Press release

Evonik breaks ground on $220 million Lipid Innovation Center in Lafayette, Indiana

29 March 2023

- Secures U.S-made key pharmaceutical excipients for RNA-based therapies for innovative medicines and pandemic preparedness
- Cooperative agreement with U.S. Government, with support from Indiana Economic Development Corporation, Greater Lafayette Commerce, and Duke Energy
- More than 80 highly skilled jobs in Greater Lafayette region

Regional press contact
Norbert Kuls
External Communications USA
Phone +1 973 437-0542
norbert.kuls@evonik.com

Robert Brown
External Communications USA
Phone +1 973 906 4635
robert.brown@evonik.com

Lafayette, IN, Evonik, one of the world's leading providers of drug delivery technologies, broke ground on its $220 million global-scale production facility for pharmaceutical lipids in Lafayette, Indiana. Representatives of the federal government, the state government as well as local officials joined Evonik's CEO Christian Kullmann and members of the company's Executive and Supervisory Boards for the groundbreaking ceremony at Evonik's Tippecanoe Laboratories.

"Our new Lipid Innovation Center will secure the health innovations of tomorrow. Through this investment we reinforce our leading position in the pharmaceutical industry. We are privileged to support the U.S. with pandemic preparedness and enable the development of cutting-edge medicines," said Christian Kullmann, CEO of Evonik.

Evonik's Lipid Innovation Center is being built on the grounds of the company's site in Tippecanoe and will position Evonik for future growth in novel mRNA-based therapies beyond COVID-19 vaccines. The investment into the lipid facility will help create more than 80 highly skilled jobs in the Greater Lafayette region. An additional 300 contractor positions will be added over the project life cycle. Production is scheduled to start in 2025.

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

"Evonik's decision to build this new facility, and add 80 high-paying jobs, in Indiana is reflective of our state's highly trained workforce and the business-friendly environment we have worked to create," said Indiana Governor Eric J. Holcomb. "We are proud to support this life science related project."

The Lafayette-based site is preferred due to its existing infrastructure, skilled workforce, and readily available technologies. Evonik currently employs nearly 680 people at its Tippecanoe site – plus an additional 150 contractors that assist with maintenance and logistics. The facility is one of the world's largest contract manufacturing facilities for active pharmaceutical ingredients (APIs) and Evonik's second-largest site in the U.S.

The total investment into the commercial-scale lipid facility amounts to $220 million. The U.S. government has entered a cooperative agreement with Evonik for a cost share of up to $150 million through its Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). BARDA promotes the advanced development of medical countermeasures to respond to 21st century health security threats and coordinated acquisition assistance with the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Additional support comes from the Indiana Economic Development Corporation (IEDC), Greater Lafayette Commerce (GLC), and Duke Energy.

"Evonik's strategic expansion at Tippecanoe is fantastic news for the entire Greater Lafayette region," said Scott Walker, president, and CEO of Greater Lafayette Commerce. "The Town of Shadeland, Lafayette, West Lafayette, Tippecanoe County, the Purdue Research Foundation, and Greater Lafayette Commerce all supported this effort and not only look forward to the high-value jobs it will create, but also

the important role the new Lipid Innovation Center will play in our nation's vaccine preparedness."

During the COVID-19 pandemic, Evonik emerged as a key partner for leading vaccine producers in securing the availability of pharmaceutical lipids. These are molecules that make up the building blocks of living cells. In novel mRNA vaccines, they protect the messenger RNA (mRNA) and ensure its safe delivery into the cell. Lipids will also be crucial for future applications of mRNA technology in infectious disease control, cancer immunotherapy, protein replacement and gene therapy.

As a leader in advanced drug delivery, Evonik supports pharma customers worldwide with comprehensive services for developing and manufacturing complex parenteral and oral drug products from early development to commercialization.

Photos can be downloaded from this link:
https://evonik.canto.global/b/QSOLK

Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

Disclaimer
(1) In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations, or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations, or statements contained in this release.

(2) The Army Contracting Command – Aberdeen Proving Ground – COVID Response is the awarding and administering acquisition office. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the JPEO-CBRND, through the Industrial Base Expansion program under cooperative agreement number W58P05-22-2-0006. Opinions, interpretations, conclusions and

recommendations are those of the author and do not imply or constitute DOD or U.S. government endorsement.